To participate in the conference call, please dial the appropriate number below five minutes prior to the call:
US: +1 877 423 0830
UK: +44 20 7153 9154
Norway: +47 21 06 61 13
Sweden: +46 8-506 443 86
Denmark: +45 32 71 42 62
Switzerland: +41 44 580 65 22
Participant pin code: 873878#
To access the replay, please dial:
US: +1 877 679 2989
UK: +44 203 364 5200
Norway: +47 23 50 02 03
Sweden: +46 8-505 564 73
Conference reference: 348995#
A replay of the conference call will also be available at www.algeta.com.
The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET.
###
For further information, please contact:
Mike Booth | +1 646 410 1884 |
Communications & Corporate Affairs | ir@algeta.com |
Media enquiries: | |
Mark Swallow | +44 207 638 9571 |
Citigate Dewe Rogerson | mark.swallow@citigatedr.co.uk |
Knut Ekern | +47 22 04 82 00 |
Gambit Hill & Knowlton | knut.ekern@hkstrategies.com |
Kari Watson | +1 781 235 3060 |
MacDougall Biomedical Communications | kwatson@macbiocom.com |
Investor enquiries: | |
Tricia Truehart | +1 646 378 2953 |
The Trout Group | ttruehart@troutgroup.com |
About Algeta
Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
distributed by |